DAPT

DOACs After Left Atrial Appendage Closure: Enhancing Safety Without Compromising Efficacy in the ANDES Trial

The ANDES randomized trial demonstrates that 60-day DOAC therapy post-LAAC significantly reduces bleeding events compared to DAPT, while maintaining comparable rates of device-related thrombosis, suggesting a superior safety profile for sho

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial